Cipla Limited announced that it has received final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for esomeprazole for oral suspension 10mg, 20mg and 40mg. Cipla is the first company to file for the 10mg strength.
Cipla's Esomeprazole for oral suspension 10mg, 20mg and 40mg is AB rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical's Nexium.
It is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease (GERD), risk reduction of NSAID-associated gastric ulcer, H pylori eradication to reduce the risk of duodenal ulcer recurrence and pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
According to IQVIA (IMS Health), Nexium and its generic equivalents had US sales of approximately $70 million for the 12 month period ending November 2019. The product is available for shipping immediately
Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for sumatriptan nasal spray, 20 mg from the United States Food and Drug Administration (FDA).
Cipla's sumatriptan nasal spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline's Imitrex nasal spray.
Imitrex nasal spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
According to IQVIA (IMS Health), Imitrex nasal spray 20mg and its generic equivalents had US sales of approximately $53.3 million for the 12-month period ending December 2020.